BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

556 related articles for article (PubMed ID: 23043035)

  • 1. Drug-eluting stenting of saphenous vein graft versus native coronary artery supplying the same myocardial perfusion territory: a pilot retrospective 3-year follow-up.
    Ho PC; Lee AC; Fortuna R
    J Invasive Cardiol; 2012 Oct; 24(10):516-20. PubMed ID: 23043035
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term comparison of everolimus-eluting stents with sirolimus- and paclitaxel-eluting stents for percutaneous coronary intervention of saphenous vein grafts.
    Taniwaki M; Räber L; Magro M; Kalesan B; Onuma Y; Stefanini GG; van Domburg RT; Moschovitis A; Meier B; Jüni P; Serruys PW; Windecker S
    EuroIntervention; 2014; 9(12):1432-40. PubMed ID: 24064377
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term outcome following percutaneous coronary intervention with drug-eluting stents compared with bare-metal stents in saphenous vein graft lesions: from Western Denmark Heart Registry.
    Hougaard M; Thayssen P; Kaltoft A; Tilsted HH; Maeng M; Lassen JF; Thuesen L; Okkels Jensen L
    Catheter Cardiovasc Interv; 2014 Jun; 83(7):1035-42. PubMed ID: 24311384
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Meta-analysis of everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease: final 3-year results of the SPIRIT clinical trials program (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions).
    Dangas GD; Serruys PW; Kereiakes DJ; Hermiller J; Rizvi A; Newman W; Sudhir K; Smith RS; Cao S; Theodoropoulos K; Cutlip DE; Lansky AJ; Stone GW
    JACC Cardiovasc Interv; 2013 Sep; 6(9):914-22. PubMed ID: 24050859
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 5-year results of a randomized comparison of XIENCE V everolimus-eluting and TAXUS paclitaxel-eluting stents: final results from the SPIRIT III trial (clinical evaluation of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions).
    Gada H; Kirtane AJ; Newman W; Sanz M; Hermiller JB; Mahaffey KW; Cutlip DE; Sudhir K; Hou L; Koo K; Stone GW
    JACC Cardiovasc Interv; 2013 Dec; 6(12):1263-6. PubMed ID: 24239202
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic total occlusion treatment in post-CABG patients: saphenous vein graft versus native vessel recanalization-long-term follow-up in the drug-eluting stent era.
    Meliga E; García-García HM; Kukreja N; Daemen J; Tanimoto S; Ramcharitar S; van Mieghem CA; Sianos G; van der Ent M; van der Giessen WJ; de Feyter P; van Domburg R; Serruys PW
    Catheter Cardiovasc Interv; 2007 Jul; 70(1):21-5. PubMed ID: 17584913
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sealing Intermediate Nonobstructive Coronary Saphenous Vein Graft Lesions With Drug-Eluting Stents as a New Approach to Reducing Cardiac Events: A Randomized Controlled Trial.
    Rodés-Cabau J; Jolly SS; Cairns J; Mansour S; L'Allier PL; Teefy PJ; Graham JJ; Le May MR; Cantor WJ; Wood D; Balasubramanian K; DeLarochellière R; Dzavik V;
    Circ Cardiovasc Interv; 2016 Nov; 9(11):. PubMed ID: 27815344
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In-hospital and 1-year outcomes with drug-eluting versus bare metal stents in saphenous vein graft intervention: a report from the EVENT registry.
    Tolerico PH; Cohen DJ; Kleiman NS; Berger PB; Brilakis ES; Piana RN; Shammo S; Keyes MJ; Kennedy KF; Massaro JM; Saucedo JF;
    Catheter Cardiovasc Interv; 2012 Dec; 80(7):1127-36. PubMed ID: 22431166
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and effectiveness of drug-eluting versus bare-metal stents in saphenous vein bypass graft percutaneous coronary interventions: insights from the Veterans Affairs CART program.
    Aggarwal V; Stanislawski MA; Maddox TM; Nallamothu BK; Grunwald G; Adams JC; Ho PM; Rao SV; Casserly IP; Rumsfeld JS; Brilakis ES; Tsai TT
    J Am Coll Cardiol; 2014 Oct; 64(17):1825-36. PubMed ID: 25443706
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A clinical and angiographic study of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with multivessel coronary artery disease: the EXECUTIVE trial (EXecutive RCT: evaluating XIENCE V in a multi vessel disease).
    Ribichini F; Romano M; Rosiello R; La Vecchia L; Cabianca E; Caramanno G; Milazzo D; Loschiavo P; Rigattieri S; Musarò S; Pironi B; Fiscella A; Amico F; Indolfi C; Spaccarotella C; Bartorelli A; Trabattoni D; Della Rovere F; Rolandi A; Beqaraj F; Belli R; Sangiorgio P; Villani R; Berni A; Sheiban I; Lopera Quijada MJ; Cappi B; Ribaldi L; Vassanelli C;
    JACC Cardiovasc Interv; 2013 Oct; 6(10):1012-22. PubMed ID: 24055444
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of clinical outcomes in patients presenting with an acute coronary syndrome due to stent thrombosis or saphenous vein graft occlusion and undergoing percutaneous coronary intervention.
    Ota H; Mahmoudi M; Lhermusier T; Magalhaes MA; Torguson R; Satler LF; Suddath WO; Pichard AD; Waksman R
    Cardiovasc Revasc Med; 2015 Dec; 16(8):441-6. PubMed ID: 26704310
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Three-Year Clinical and Angiographic Outcomes After Everolimus-Eluting Stent Implantation in Patients With a History of Coronary Artery Bypass Grafting.
    Nomura T; Suzuki N; Takamura S; Kyono H; Kozuma K
    Int Heart J; 2016; 57(2):158-66. PubMed ID: 26973268
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug-Eluting Versus Bare Metal Stents in Saphenous Vein Graft Intervention: An Updated Comprehensive Meta-Analysis of Randomized Trials.
    Bhogal S; Panchal HB; Bagai J; Banerjee S; Brilakis ES; Mukherjee D; Kumar G; Shanmugasundaram M; Paul TK
    Cardiovasc Revasc Med; 2019 Sep; 20(9):758-767. PubMed ID: 30503811
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Percutaneous coronary intervention of native coronary artery versus saphenous vein graft in patients with prior coronary artery bypass graft surgery: Rationale and design of the multicenter, randomized PROCTOR trial.
    de Winter RW; Walsh SJ; Hanratty CG; Spratt JC; Sprengers RW; Twisk JWR; Vegting I; Schumacher SP; Bom MJ; Hoek R; Verouden NJ; Delewi R; Nap A; Knaapen P;
    Am Heart J; 2023 Mar; 257():20-29. PubMed ID: 36410442
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of coronary anatomy and stenting technique on long-term outcome after drug-eluting stent implantation for unprotected left main coronary artery disease.
    Tiroch K; Mehilli J; Byrne RA; Schulz S; Massberg S; Laugwitz KL; Vorpahl M; Seyfarth M; Kastrati A;
    JACC Cardiovasc Interv; 2014 Jan; 7(1):29-36. PubMed ID: 24332416
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multicenter international registry of unprotected left main coronary artery percutaneous coronary intervention with everolimus-eluting stents.
    Lee MS; Park KW; Kang SH; Sheiban I; Mahmud E; Thani KB; Cheng R; Cho JH; Jin DK; Gwon HC; Chae IH; Aragon J; Gillis K; Stone GW; Kim HS
    J Invasive Cardiol; 2012 Jul; 24(7):316-9. PubMed ID: 22781468
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes after implantation of the TAXUS paclitaxel-eluting stent in saphenous vein graft lesions: results from the ARRIVE (TAXUS Peri-Approval Registry: A Multicenter Safety Surveillance) program.
    Brilakis ES; Lasala JM; Cox DA; Berger PB; Bowman TS; Starzyk RM; Dawkins KD
    JACC Cardiovasc Interv; 2010 Jul; 3(7):742-50. PubMed ID: 20650436
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plaque Sealing With Drug-Eluting Stents Versus Medical Therapy for Treating Intermediate Non-Obstructive Saphenous Vein Graft Lesions: A Pooled Analysis of the VELETI and VELETI II Trials.
    Maes F; Jolly SS; Cairns J; Delarochellière R; Côté M; Dzavik V; Rodés-Cabau J
    J Invasive Cardiol; 2019 Nov; 31(11):E308-E315. PubMed ID: 31671060
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug-eluting stenting is superior to bare metal stenting in saphenous vein grafts.
    Lee MS; Shah AP; Aragon J; Jamali A; Dohad S; Kar S; Makkar RR
    Catheter Cardiovasc Interv; 2005 Dec; 66(4):507-11. PubMed ID: 16270361
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Continued benefit from paclitaxel-eluting compared with bare-metal stent implantation in saphenous vein graft lesions during long-term follow-up of the SOS (Stenting of Saphenous Vein Grafts) trial.
    Brilakis ES; Lichtenwalter C; Abdel-karim AR; de Lemos JA; Obel O; Addo T; Roesle M; Haagen D; Rangan BV; Saeed B; Bissett JK; Sachdeva R; Voudris VV; Karyofillis P; Kar B; Rossen J; Fasseas P; Berger P; Banerjee S
    JACC Cardiovasc Interv; 2011 Feb; 4(2):176-82. PubMed ID: 21349456
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.